Back to search

University of Manitoba

Is Empagliflozin equivalent and/or synergistic with ACE inhibition in the treatment of chemotherapy mediated cardiotoxicity?

Abstract

dc:description.abstract

Background: Doxorubicin and Trastuzumab (DOX+TRZ) are two of the most commonly used anti-cancer medications for treating breast cancer. Although these two drugs enhance overall survival rates in women with breast cancer, they are associated with an increased risk of cardiotoxicity. Various randomized controlled trials have demonstrated that sodium-glucose co-transporter 2 (SGLT2) inhibitors, such as Empagliflozin (EMPA), reduce the risk of hospitalizations and mortality due to heart failure in patients with and without diabetes. However, little is known about the potential effects of SGLT2 inhibitors in treating DOX+TRZ mediated cardiotoxicity. Objective: The objective of this thesis is to assess whether the effectiveness of the SGLT2 inhibitor EMPA treatment is similar to and/or synergistic with the standard drug therapy using the RAS inhibitor perindopril (PER) in treating DOX+TRZ-induced cardiomyopathy. Methods: For the 6-week study, a total of 130 C57Bl/6 female mice were randomly assigned to receive weekly treatment with saline (n = 30) or DOX+TRZ (n = 100) intraperitoneally for 3 weeks to establish a chronic in vivo murine model of chemotherapy induced cardiotoxicity. Mice were treated with PER (3 mg/kg), EMPA (10 mg/kg) or EMPA+PER by oral gavage for an additional 3 weeks for a total of 6 weeks. Echocardiography was performed on a weekly basis and at the end of week 6, the mice were euthanized for histological and biochemical analyses. Results: In mice treated with DOX+TRZ (n=15), the left ventricular ejection fraction (LVEF) decreased from 74±4% at baseline to 37±6% at week 6. Mice treated with either PER, EMPA, or EMPA+PER via oral gavage demonstrated an improvement in LVEF of 62±4%, 63±3%, and 64±4%, respectively (p<0.05) (Figure 1). Histological analyses confirmed significant disruption of myofibrils, vacuolization, and loss of sarcomere integrity in the DOX+TRZ treated mice. Oral gavage with EMPA and EMPA+PER, however, improved myofibril integrity at week 6 in mice receiving DOX+TRZ. Finally, the Bax/Bcl-xL ratio, a marker of apoptotic signalling, was significantly increased by approximately 2-fold in mice receiving DOX+TRZ on Western analyses. This increase was attenuated by treatment with PER, EMPA, or the combination of EMPA+PER. Conclusion: EMPA was equivalent to PER in the treatment of DOX+TRZ mediated cardiotoxicity.

Degree

thesis:*
Level thesis:degree_level
Master of Science (M.Sc.)
Discipline thesis:degree_discipline
Physiology and Pathophysiology
Year dc:date.issued
2026

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Ali, Sumha
Advisor dc:contributor.supervisor
  • Jassal, Davinder
Committee members dc:contributor.committeemember
  • Ravandi, Amir (Internal Medicine)
  • Dhingra, Sanjiv (Physiology and Pathophysiology)
  • Wigle, Jeffrey (Biochemistry and Medical Genetics)

Subjects

dc:subject × 10

Rights

Language dc:language.iso
eng

Identifiers

dc:identifier.*
Handle dc:identifier.uri
http://hdl.handle.net/1993/39733

Chain of custody

source
Harvested from
University of Manitoba
Base URL
mspace.lib.umanitoba.ca/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Ali, Sumha. Is Empagliflozin equivalent and/or synergistic with ACE inhibition in the treatment of chemotherapy mediated cardiotoxicity?. Master of Science (M.Sc.) thesis, 2026. http://hdl.handle.net/1993/39733